J.P. Morgan analyst Robbie Marcus has maintained their neutral stance on EW stock, giving a Hold rating on July 28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Robbie Marcus has given his Hold rating due to a combination of factors surrounding Edwards Lifesciences. The company’s recent announcement regarding the Federal Trade Commission’s move to block its acquisition of JenaValve has led to an expected delay in the deal’s closure until the end of the first quarter of 2026. This delay is anticipated to have a minimal impact on the company’s earnings per share for the year, with a slight increase expected due to the postponement of JenaValve’s dilution.
Despite this setback, the consensus estimates currently reflect minimal contribution from the JenaValve deal, suggesting that the overall financial outlook for Edwards Lifesciences remains relatively stable. Consequently, Robbie Marcus believes that the current numbers do not require significant adjustments, supporting his decision to maintain a Hold rating on the stock.
In another report released on July 28, Bernstein also maintained a Hold rating on the stock with a $85.00 price target.
Based on the recent corporate insider activity of 102 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year.